2-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methyl-pyridin-2-yl-amino]-ethanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methyl-pyridin-2-yl-amino]-ethanol
• 英文别名: 2-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-6-methyl-pyridin-2-ylamino]-ethanol；2-[[4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methylpyridin-2-yl]amino]ethanol
• 化学式: C₁₇H₂₁N₃O
• 分子量: 283.373
• InChiKey: HOPVAQQEEJHKLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  48.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,4-二溴-6-甲基吡啶 在 ammonium hydroxide 、 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 2-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methyl-pyridin-2-yl-amino]-ethanol
  参考文献：
  名称：

  4-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists

  摘要：

  A series of 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and analogous quinolines was prepared and evaluated as NR1/2B subtype selective NMDA receptor antagonists. 2-Hydroxyalkylamino substitution combines high affinity with selectivity (vs alpha1 and M1 receptors) and activity in vivo. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00232-4

文献信息

• Pyridine substituted isoquinoline derivatives
  申请人：——

  公开号：US20030119870A1

  公开（公告）日：2003-06-26

  The invention relates to compounds of formulae 1 Compounds of the invention have a good affinity to the NMDA receptor and are useful for the treatment of diseases related to this receptor.

  该发明涉及公式1的化合物。该发明的化合物对NMDA受体具有良好的亲和力，并且可用于治疗与该受体相关的疾病。
• PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1448547B1

  公开（公告）日：2005-04-20
• US6831087B2
  申请人：——

  公开号：US6831087B2

  公开（公告）日：2004-12-14
• [EN] PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE PYRIDINE UTILISÉS COMME LIGANDS DU RÉCEPTEUR NMDA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003040128A1

  公开（公告）日：2003-05-15

  The invention relates to compounds of formulas (IA) or (IB) wherein R1 and R2 are independently from each other hydrogen, lower alkyl, -(CH2)n-OH, -(CH2)n-N(R6)2, -NR6C(O)C(O)O-lower alkyl, -NR6-(CH2)n-OH, -NR6C(O)-lower alkyl, -NH-benzyl or NR6C(O)-(CH2)n-OH; R6 is independently from each other hydrogen or lower alkyl R' is hydrogen or lower alkyl; R3 is hydrogen or amino; R4 is hydrogen or lower alkyl; R5 is hydrogen or halogen; or R1 and R' may be together with the carbon atoms to which they are attached the group (CH2)4-; or R2 and R3 may be together with the carbon atoms to which they are attached the group -N(R6)-CH2-O-CH2-; n is 0, 1, 2 or 3; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that these compounds have a good affinity to the NMDA receptor and they may therefore be used for the treatment of diseases, related to this receptor.